PMID- 23969014
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20151119
IS  - 1096-0309 (Electronic)
IS  - 0003-2697 (Linking)
VI  - 443
IP  - 1
DP  - 2013 Dec 1
TI  - Enhancement of ovarian tumor classification by improved reproducibility in 
      matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of 
      serum glycans.
PG  - 58-65
LID - S0003-2697(13)00378-3 [pii]
LID - 10.1016/j.ab.2013.07.048 [doi]
AB  - The serum N-glycome is a promising source of biomarker discovery. Matrix-assisted 
      laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) 
      profiling of serum N-glycans was attempted for differentiating borderline ovarian 
      tumor from benign cases, for which a low data spread is essential. An 
      experimental protocol using matrix-prespotted MALDI plates and fast vacuum drying 
      of the loaded N-glycan samples was developed, thereby minimizing the intensity 
      variations in the replicates to an average relative standard deviation (RSD) of 
      3.96% for the highest N-glycan peak (m/z 1485.53) of the Sigma-Aldrich serum 
      standard. When applied to sera of ovarian tumors, this procedure exhibited an 
      average RSD of 5.74% for m/z 1485.53 and of 7.28% for all MS peaks. This improved 
      reproducibility combined with the OVA-Beyond((R)) screening software resulted in 
      75.1% and 79.4% correct classification for benign and borderline tumor samples, 
      respectively, while the classification rates by the conventional ovarian tumor 
      marker CA-125 were 54.4% and 53.1%, respectively. Both true positive rate and 
      true negative rate fluctuated with small numbers of markers and converged as the 
      number of markers increased. Cross-validations were performed in comparison with 
      CA-125. These results suggest that our optimized process for MALDI-TOF MS of the 
      serum glycome has a great potential for the screening of early stage ovarian 
      cancer.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Park, Chang Won
AU  - Park CW
AD  - ASTA, Inc., Gyeonggi Biocenter, Eui-dong, Youngtong-gu, Suwon 443-270, South 
      Korea.
FAU - Jo, Yohahn
AU  - Jo Y
FAU - Jo, Eung Joon
AU  - Jo EJ
LA  - eng
PT  - Journal Article
DEP - 20130819
PL  - United States
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Polysaccharides)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/*blood
MH  - CA-125 Antigen/blood
MH  - Cystadenoma, Mucinous/*blood/diagnosis
MH  - Cystadenoma, Serous/*blood/diagnosis
MH  - Diagnosis, Differential
MH  - Endometriosis/blood/diagnosis
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Ovarian Neoplasms/*blood/diagnosis
MH  - Polysaccharides/*blood
MH  - Reproducibility of Results
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Teratoma/*blood/diagnosis
OTO - NOTNLM
OT  - MALDI-TOF
OT  - Mass spectrometry
OT  - Matrix-prespotted plate
OT  - N-glycan
OT  - RSD
EDAT- 2013/08/24 06:00
MHDA- 2014/05/07 06:00
CRDT- 2013/08/24 06:00
PHST- 2013/03/23 00:00 [received]
PHST- 2013/07/26 00:00 [revised]
PHST- 2013/07/31 00:00 [accepted]
PHST- 2013/08/24 06:00 [entrez]
PHST- 2013/08/24 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
AID - S0003-2697(13)00378-3 [pii]
AID - 10.1016/j.ab.2013.07.048 [doi]
PST - ppublish
SO  - Anal Biochem. 2013 Dec 1;443(1):58-65. doi: 10.1016/j.ab.2013.07.048. Epub 2013 
      Aug 19.